1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

What Teva's $1.2bn settlement means for pay for delay

 
• By Donna Young

Drug manufacturer giant Teva was practically at the courthouse steps when it settled on 28 May for $1.2bn with the US Federal Trade Commission (FTC) over what the agency said were illegal efforts by the company's subsidiary Cephalon to block US generic competition of its $1bn blockbuster narcolepsy and sleep apnea drug Provigil (modafinil).

Drug manufacturer giant Teva was practically at the courthouse steps when it settled on 28 May for $1.2bn with the US Federal Trade Commission (FTC) over what the agency said were illegal efforts by the company's subsidiary Cephalon to block US generic competition of its $1bn blockbuster narcolepsy and sleep apnea drug Provigil (modafinil).

The FTC's lawsuit against Teva, filed in 2008, was set to go to trial 1 June.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from Therapy Areas

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.